Secukinumab failure in Crohn's disease: the yeast connection?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

44 citing papers in PubMed.

1. Specific fungi associated with response to capsulized fecal microbiota transplantation in patients with active ulcerative colitis.Frontiers in cellular and infection microbiology · 2022
   Trial
2. Psoriatic Arthritis: From Diagnosis to Treatment.Journal of clinical medicine · 2025
   Review
3. Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease.European journal of medical research · 2025
   Article
4. Secukinumab-induced Crohn's disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition.Frontiers in immunology · 2025
   Article
5. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease.Frontiers in immunology · 2024
   Review
6. Mucosal Immunity to Gut Fungi in Health and Inflammatory Bowel Disease.Journal of fungi (Basel, Switzerland) · 2023
   Review
7. Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment.International journal of molecular sciences · 2023
   Review
8. The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors.Biomedicines · 2023
   Review
9. Psoriatic Arthritis: Pathogenesis and Targeted Therapies.International journal of molecular sciences · 2023
   Review
10. Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors.International journal of molecular sciences · 2023
    Article
11. Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets.Drugs · 2022
    Article
12. Fungal Colonization and Infections-Interactions with Other Human Diseases.Pathogens (Basel, Switzerland) · 2022
    Review
13. Update: Innate Lymphoid Cells in Inflammatory Bowel Disease.Digestive diseases and sciences · 2022
    Review
14. A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role ofJournal of fungi (Basel, Switzerland) · 2021
    Article
15. Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting.Cellular & molecular immunology · 2021
    Review
16. The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights.Seminars in immunopathology · 2021
    Review
17. Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
18. Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.Nature reviews. Rheumatology · 2020
    Review
19. Interleukin-17 Inhibition in Spondyloarthritis Is Associated With Subclinical Gut Microbiome Perturbations and a Distinctive Interleukin-25-Driven Intestinal Inflammation.Arthritis & rheumatology (Hoboken, N.J.) · 2020
    Article
20. Bugs, Drugs, and Shrugs.Arthritis & rheumatology (Hoboken, N.J.) · 2020
    Article

Corrections and comments

• Comment on
  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.2012

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as